IPO7 and familial pancreatic carcinoma: Taken together, we demonstrate that IPO7 expression is up-modulated in pancreatic cancer tissues as well as cell lines, and its overexpression implies shorter survival time of the patients, suggesting that it may serve as a promising biomarker for evaluating the prognosis of patients with pancreatic cancer.